ARTA
LCTX icon

A.R.T. Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

A.R.T. Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,825
Closed -$11K – 181
2020
Q2 		$11K Buy
+12,825
New +$11.3K 0.02% 271
2020
Q1 		– Sell
-32,225
Closed -$29K – 561
2019
Q4 		$29K Buy
32,225
+19,594
+155% +$16.3K ﹤0.01% 1272
2019
Q3 		$12K Sell
12,631
-17,100
-58% -$17.7K ﹤0.01% 1383
2019
Q2 		$33K Buy
+29,731
New +$34.3K ﹤0.01% 1274
2019
Q1 		– Sell
-53,313
Closed -$49K – 1464
2018
Q4 		$49K Buy
+53,313
New +$81.7K ﹤0.01% 1218
2018
Q3 		– Sell
-13,294
Closed -$23K – 1553
2018
Q2 		$23K Sell
13,294
-87,331
-87% -$176K ﹤0.01% 1359
2018
Q1 		$236K Sell
100,625
-13,819
-12% -$32.4K 0.01% 1217
2017
Q4 		$215K Buy
114,444
+85,476
+295% +$187K 0.01% 1138
2017
Q3 		$71K Sell
28,968
-7,247
-20% -$18K ﹤0.01% 1233
2017
Q2 		$99K Buy
+36,215
New +$101K 0.01% 1255

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

A.R.T. Advisors's LCTX Position: Q3 2020 in Review

A.R.T. Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 12,825 shares — an estimated $11K sold.

A.R.T. Advisors first reported a position in LCTX in Q2 2017 and held it in 10 quarters. The position peaked at $236K in Q1 2018. 75 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • A.R.T. Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 12,825 Lineage Cell Therapeutics shares in Q3 2020, an estimated $11K.
  • A.R.T. Advisors first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 10 quarters.
  • A.R.T. Advisors's Lineage Cell Therapeutics position peaked at $236K in Q1 2018.
  • 75 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.